Sacituzumab does not improve outcomes vs chemotherapy when used as the first treatment after endocrine therapy failure in HR+/HER2- advanced breast cancer, the ASCENT-07 trial finds.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/sacituzumab-before-chemo-misses-mark-breast-cancer-trial-2025a1000ypm?src=rss
Author :
Publish date : 2025-12-11 04:26:00
Copyright for syndicated content belongs to the linked Source.
